Evaluation of early response by FDG-PET in breast cancers treated with neoadjuvant chemotherapy

• Project/Area Number: 26461963
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Hyogo Medical University
• Principal Investigator: Miyoshi Yasuo 兵庫医科大学, 医学部, 教授 (50283784)
• Co-Investigator(Kenkyū-buntansha): 柳井 亜矢子 兵庫医科大学, 医学部, その他 (00529159) ; 北島 一宏 兵庫医科大学, 医学部, 准教授 (80448860) ; 樋口 智子 兵庫医科大学, 医学部, 病院助手 (50786407)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
• Keywords: 乳癌 / FDG-PET / 化学療法 / 感受性 / SUVmax / TIL / Ki67 / Geminin / 術前化学療法

Outline of Final Research Achievements

We have evaluated SUVmax values (indicator of glucose uptake) in 163 breast cancers and identified that proliferative marker geminin and tumor size were significant indicators for SUVmax. During tumor progression such as increase of tumor size and proliferation, upregulation of glucose uptake which can be estimated by SUVmax seems to be required.
We examined usefulness of metabolic parameters for predicting efficacy of chemotherapy. In addition to SUVmax value, 2-dimensional indicator, and 3-dimensional MTV and TLG are examined in terms of pathological complete response (pCR) in 182 breast cancers treated with neoadjuvant chemotherapy. Baseline MTV was a significant predictor for pCR. Furthermore, reduction rates of SUVmax after one cycle treatment significantly associated with pCR. Combination of MTV and change of SUVmax accurately predict pCR. We identified that combination of MTV and SUVmax change is useful for predicting efficacy of chemotherapy in breast cancers.

Research Products

• [Journal Article] Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. (2018)
  • Author(s): Kitajima K, Miyoshi Y, Yamano T, Odawara S, Higuchi T, Yamakado K.
  • Journal Title: Ann Nucl Med. Volume: 32 Issue: 1 Pages: 44-53
  • DOI: 10.1007/s12149-017-1217-9
  • NAID: 120006534983
  • Peer Reviewed
• [Journal Article] Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers (2017)
  • Author(s): Nishimukai Arisa、Inoue Natsuko、Kira Ayako、Takeda Masashi、Morimoto Koji、Araki Kazuhiro、Kitajima Kazuhiro、Watanabe Takahiro、Hirota Seiichi、Katagiri Toyomasa、Nakamori Shoji、Akazawa Kouhei、Miyoshi Yasuo
  • Journal Title: PLOS ONE Volume: Vol.12, No.9 Issue: 9 Pages: e0184508-e0184508
  • DOI: 10.1371/journal.pone.0184508
  • NAID: 120006534983
  • Peer Reviewed / Open Access
• [Journal Article] Prognostic significance of preoperative ¹⁸F-FDG PET/CT for breast cancer subtypes. (2016)
  • Author(s): Higuchi T, Nishimukai A, Ozawa H, Fujimoto Y, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Kitajima K, Fukushima K, Miyoshi Y.
  • Journal Title: Breast Volume: 30 Pages: 5-12
  • DOI: 10.1016/j.breast.2016.08.003
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer. (2016)
  • Author(s): Kitajima K, Fukushima K, Miyoshi Y, Katsuura T, Igarashi Y, Kawanaka Y, Mouri M, Maruyama K, Yamano T, Doi H, Yamakado K, Hirota S, Hirota S.
  • Journal Title: Jpn J Radiol. Volume: 34(3) Issue: 3 Pages: 220-228
  • DOI: 10.1007/s11604-015-0515-1
  • NAID: 210000178391
  • Peer Reviewed / Open Access
• [Journal Article] Present and future role of FDG-PET/CT imaging in the management of breast cancer. (2016)
  • Author(s): Kitajima K, Miyoshi Y.
  • Journal Title: Jpn J Radiol. Volume: 34(3) Issue: 3 Pages: 167-180
  • DOI: 10.1007/s11604-015-0516-0
  • NAID: 50009768826
  • Peer Reviewed / Open Access
• [Journal Article] Association between 18F-FDG uptake and molecular subtype of breast cancer. 2015 May 7. [Epub ahead of print] (2015)
  • Author(s): Kitajima K, Fukushima K, Miyoshi Y, Nishimukai A, Hirota S, Igarashi Y, Katsuura T, Maruyama K, Hirota S.
  • Journal Title: European Journal of Nuclear Medicine and Molecular Imaging Volume: online Issue: 9 Pages: 1371-1377
  • DOI: 10.1007/s00259-015-3070-1
  • Peer Reviewed / Open Access
• [Presentation] 原発性乳癌におけるFDG-PETのSUVmax値を規定している因子の同定 (2017)
  • Author(s): 井上 奈都子、樋口 智子、西向 有沙、藤本 由希枝、柳井 亜矢子、宮川 義仁、村瀬 慶子、文 亜也子、盛本 浩二、今村 美智子、高塚 雄一、山野 理子、荒木 和浩、三好 康雄
  • Organizer: 第25回日本乳癌学会学術総会
• [Presentation] FDG-PET におけるSUVmax値のサブタイプ別予後因子としての意義 (2016)
  • Author(s): 樋口智子、西向有沙、尾澤宏美、柳井亜矢子、宮川義仁、村瀬慶子、今村美智子、高塚雄一、山野理子、三好康雄
  • Organizer: 第24回 日本乳癌学会学術総会
  • Place of Presentation: 東京ビッグサイト（東京）
  • Year and Date: 2016-06-16
• [Presentation] FDG-PETにおけるSUVmax値のサブタイプ別予後因子としての意義 (2016)
  • Author(s): 樋口 智子, 西向 有沙, 尾澤 宏美, 柳井 亜矢子, 宮川 義仁, 村瀬 慶子 ,今村 美智子, 高塚 雄一, 山野 理子, 三好 康雄．
  • Organizer: 第24回日本乳癌学会学術総会
  • Place of Presentation: 東京ビッグサイト（東京）
• [Presentation] エストロゲン受容体陽性・HER2陰性乳癌のFDG-PETにおけるSUVmax値と増殖能との相関 (2016)
  • Author(s): 井上 奈都子, 樋口 智子, 西向 有沙, 尾澤 宏美, 柳井 亜矢子, 宮川 義仁, 村瀬 慶子, 今村 美智子, 高塚 雄一, 山野 理子, 三好 康雄.
  • Organizer: 第24回日本乳癌学会学術総会
  • Place of Presentation: 東京ビッグサイト（東京）